CURRENT PAPERS:
Three Phases of the Pharmacy Benefit Manager Business Model (09/17)
Will Amazon’s Online Pharmacy Display Therapeutic Equivalents (12/17)
Blame PBMs (Not Pharma) For Driving Drug Price Inflation (09/17)
Merck Data Discredits PBM-Sponsored Study of Brand Drug Price Inflation (09/17)
Biosimilars and Exclusive Dealing Antitrust Law: The Case of Pfizer Inc vs J&J et al (12/17)
Hepatitis C Virus Formulary Choices for 2018: Will CVS Caremark Risk Looking Bad? (09/17)
AbbVie’s Mavyret Hep C Drug Pricing is Disruptive to the PBM Business Model (09/17)
PAST PAPERS:
Pharmacy Benefit Managers as Conflicted Countervailing Powers (01/07)
Pharmacy Benefit Manager Valuation and Profitability: Business Models Matter (07/09)
Medco As a Business Model Imperialist (07/08)
The Express Scripts – Wellpoint (Anthem) Deal as a “Double-Trouble” Front (08/09)
Quantifying Medco’s Business Model: An Update (11/08)
A Tale of Two PBMs: Express Scripts vs. Medco (11/05)
Searching for Windfall Profits from a Change in the AWP Markup Ratio (09/09)
Exclusionary Practices in the Mail Order Pharmacy Market (09/05)
Quantifying Medco’s Business Model (04/05)
Estimating the Rebate-Retention Rate of Pharmacy Benefit Managers (04/03)
Walgreen’s Transparency Issue (11/03)
